Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

539 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Moore KN, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, O'Malley DM, Banerjee S, Murphy CG, Harter P, Konecny GE, Pautier P, Method M, Wang Y, Coleman RL, Birrer M, Matulonis UA. Moore KN, et al. Among authors: lorusso d. Gynecol Oncol. 2024 Dec;191:249-258. doi: 10.1016/j.ygyno.2024.10.013. Epub 2024 Oct 25. Gynecol Oncol. 2024. PMID: 39461270
Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era.
Creutzberg CL, Kitchener HC, Birrer MJ, Landoni F, Lu KH, Powell M, Aghajanian C, Edmondson R, Goodfellow PJ, Quinn M, Salvesen HB, Thomas G; GCIG Endometrial Cancer Clinical Trials Planning Meeting. Creutzberg CL, et al. Int J Gynecol Cancer. 2013 Oct;23(8):1528-34. doi: 10.1097/IGC.0b013e3182a26edb. Int J Gynecol Cancer. 2013. PMID: 24257568
Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors.
Brown J, Friedlander M, Backes FJ, Harter P, O'Connor DM, de la Motte Rouge T, Lorusso D, Maenpaa J, Kim JW, Tenney ME, Seckl MJ. Brown J, et al. Among authors: lorusso d. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S48-54. doi: 10.1097/IGC.0000000000000223. Int J Gynecol Cancer. 2014. PMID: 25341580 Review.
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
Konecny GE, Finkler N, Garcia AA, Lorusso D, Lee PS, Rocconi RP, Fong PC, Squires M, Mishra K, Upalawanna A, Wang Y, Kristeleit R. Konecny GE, et al. Among authors: lorusso d. Lancet Oncol. 2015 Jun;16(6):686-94. doi: 10.1016/S1470-2045(15)70159-2. Epub 2015 May 13. Lancet Oncol. 2015. PMID: 25981814 Free article. Clinical Trial.
539 results